A retrospective, observational study evaluating the gastric acid suppression effect on efficacy of erlotinib and gefitinib in patients with non-small-cell lung carcinoma

Trial Profile

A retrospective, observational study evaluating the gastric acid suppression effect on efficacy of erlotinib and gefitinib in patients with non-small-cell lung carcinoma

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Jul 2016

At a glance

  • Drugs Erlotinib (Primary) ; Gefitinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Jul 2016 New trial record
    • 07 Jun 2016 Results assessing the impact of gastric suppression on progression free survival presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top